MET and hepatocellular carcinoma: Volitinib (Savolitinib), SAR125844, tepotinib (EMD1214063), capmatinib (INCB28060), AMG337, Indo5, tivantinib, and PHA665752 are of such selective c-Met inhibitors [156–160], which showed anti-tumor effects in various cancers with high MET expression, including gastric and hepatocellular carcinoma, papillary renal carcinoma, and NSCLC [158, 161].